Pharma Pulse 9/13/24: AI Adoption for Clinical Trial Design, Comparing Biologics and Biosimilars & more

AI Adoption for Clinical Trial Design, Planning

An overview of the advantages of implementing AI into clinical development and the obstacles that prevent its widespread adoption.

Comparing Biologics and Biosimilars

Sophia Humphreys, PharmD, MHA, BCBBS, discusses the key differences between biologics and biosimilars.

OpenAI’s Fund-Raising Talks Could Value Company at $150 Billion

The San Francisco start-up hopes to raise $6.5 billion as part of an aggressive push for more investment.

Dr.Evidence Unveils Major Enhancements to AI-enabled Landscape Intelligence Platform for Life Sciences

Dr.Evidence announced significant enhancements to further accelerate clients’ time-to-market for new drugs and indications and de-risk the possibility of missing critical precedent from the market to support a successful path to approval.

Gary Hagestad on LinkedIn

GelSana has a great story to tell! Great interview with Mike Hennessey, Jr. So much innovation coming out of Colorado's life sciences ecosystem!

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs